SASarah Ashley

Sarah Ashley

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sarah Ashley has a total of 145 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Three‐Year Post‐Treatment Outcomes Following Cessation of Peanut Oral Immunotherapy: Comparisons by Clinical Allergy Status and Treatment Group

    by Paxton Loke, Xiaofang Wang, Sophie Rosser, Melanie Lloyd, Sarah E. Ashley, Adriana C. Lozinsky, Julie Burns, Patrick Quinn, Michael D. O'SUllivan, Michael Gold, et al.

  • Open Access

    Correlation and Agreement Between Parent‐Report and Self‐Report Food Allergy Quality of Life Questionnaires After Oral Immunotherapy

    by Sophie A. Rosser, Melanie Lloyd, Rachel L. Peters, Rushani Wijesuriya, Paxton Loke, Sarah E. Ashley, Adriana Chebar Lozinsky, Mimi L. K. Tang

    Summary Box: We observed moderate correlation, but limited agreement, between parent‐ and self‐report FAQLQ instruments post‐treatment. FAQLQ instruments are not interchangeable, with score differences exceeding clinically acceptable thresholds.

  • Probiotic oral immunotherapy for egg and milk allergy induces sustained unresponsiveness

    by Melanie Lloyd, Paxton Loke, Kathy Nguyen, Sigrid Pitkin, Sarah Ashley, Andy Cantlay, Julie Burns, Hugh Brown, Francesca Orsini, Mimi L. K. Tang, et al.

    Background: High‐dose rapid‐escalation oral immunotherapy (OIT) with adjunct probiotic is effective at inducing sustained unresponsiveness (SU) of peanut allergy, but the efficacy of this approach for other food allergies is untested. This open‐label study aimed to confirm the safety and tolerability of high‐dose egg and milk oral immunotherapy (OIT) with probiotic in children. Methods: Participants aged 5–17 years with egg ( n = 20) or milk ( n = 20) allergy confirmed by double‐blind placebo‐controlled food challenge (DBPCFC) received probiotic and either egg or milk OIT for 18 months. SU was assessed by DBPCFC performed post‐treatment (after 8 weeks dietary allergen exclusion). The primary outcome was the proportion completing the dose‐escalation phase according to protocol. Secondary outcomes were the proportion with SU, adverse events (AE), and change in health‐related quality of life (HRQL). Results: Nine (45%) egg and 7 (35%) milk participants completed the dose‐escalation according to protocol, and 17 (85%) in both groups were able to reach the maintenance phase with dose modifications. Eleven (55%) egg and 10 (50%) milk participants attained SU. Treatment‐related AEs were frequent, with 9 (45%) egg and 13 (65%) milk participants reporting at least one moderate or severe event. Clinically significant improvements in HRQL were observed in both groups. Conclusion: High‐dose rapid‐escalation OIT with adjunct probiotic is a promising treatment for egg and milk allergy, which may increase the likelihood of achieving SU and shorten the required treatment period for participants. The efficacy and safety of this approach should be confirmed in later‐stage placebo‐controlled randomized trials.


  • Open Access

    Probiotic oral immunotherapy for egg and milk allergy induces sustained unresponsiveness

    by Melanie Lloyd, Paxton Loke, Kathy Nguyen, Sigrid Pitkin, Sarah Ashley, Andy Cantlay, Julie Burns, Hugh Brown, Francesca Orsini, Mimi Tang, et al.

    Background: High dose rapid-escalation oral immunotherapy (OIT) with adjunct probiotic is highly effective at inducing sustained unresponsiveness (SU) of peanut allergy, but the efficacy of this approach for other food allergies is untested. This open-label study aimed to confirm the safety, tolerability and long-term effects of high dose egg and milk oral immunotherapy (OIT) with probiotic in children. Methods: Participants aged 5–17 years with egg (n=20) or milk (n=20) allergy confirmed by double-blind placebo-controlled food challenge (DBPCFC) received probiotic and either egg or milk OIT for 18 months. SU was assessed by DBPCFC performed post-treatment (after 8-weeks dietary allergen exclusion). The primary outcome was proportion completing the dose-escalation phase according to protocol. Secondary outcomes were proportion with SU, adverse events (AE) and change in health-related quality of life (HRQL). Results: Nine (45%) egg, and 7 (35%) milk completed the dose-escalation according to protocol, and 17 (85%) in both groups were able to reach maintenance phase with dose modifications. Eleven (55%) egg and 10 (50%) milk participants attained SU. Treatment-related AEs were frequent, with 9 (45%) egg and 13 (65%) milk participants reporting at least one moderate or severe event. Clinically significant improvements in HRQL were observed in both groups. Conclusion: High dose rapid-escalation OIT with adjunct probiotic is a promising treatment for egg and milk allergy which may increase the likelihood of achieving SU and shorten the required treatment period for participants. The efficacy and safety of this approach should be confirmed in later-stage placebo-controlled randomised trials.

  • Open Access

    Sex assigned at birth may modify health‐related quality of life in children treated with peanut oral immunotherapy

    by Sophie A. Rosser, Melanie Lloyd, Paxton Loke, Sarah Ashley, Michael D. O'SUllivan, Patrick Quinn, Michael Gold, Mimi L. K. Tang

    Background: The high burden of peanut allergy underscores the need for treatment options that improve patient health‐related quality of life (HRQL). However, the modifying effect of sex assigned at birth on treatment‐related outcomes remains poorly understood. We sought to investigate whether sex modifies treatment effect on the change in overall and subdomain HRQL during the PPOIT‐003 trial.Methods: PPOIT‐003 was a multicenter, randomized controlled trial in 201 children with peanut allergy (aged 1–10) allocated to combined probiotic and peanut oral immunotherapy (PPOIT), peanut oral immunotherapy alone (OIT), or placebo. Participant HRQL was measured with the Food Allergy Quality of Life–Parent Form (FAQLQ‐PF) at baseline, end‐of‐treatment, and 12 months post‐treatment. Multivariable linear regression with an interaction term was used to investigate the relationship between treatment and HRQL in males (N = 128, 63.68%) and females (N = 73, 36.32%).Results: Sex‐modification of total FAQLQ‐PF scores was present between baseline to end of 12 month follow‐up (p = .008). In this time, improvement in FAQLQ‐PF scores was significantly better in active compared to placebo groups for males (PPOIT vs. Placebo: −1.003 [95% CI: −1.571, −0.436]; OIT vs. Placebo: −1.250 [95% CI: −1.805, −0.695]), but not for females where improvement also occurred in the placebo group (PPOIT vs. Placebo: −0.148 [95% CI: −0.914, 0.617]; OIT vs. Placebo: 0.252 [95% CI: −0.547, 1.052]). Separate analysis of study phases revealed sex effect modification was greater during treatment than during post‐treatment follow‐up in domains related to food anxiety (p = .037) and emotional impact of allergy (p = .063).Conclusion: Sex modifies HRQL outcomes during peanut OIT. Greater understanding of the biological and psychosocial drivers of post‐treatment HRQL will facilitate personalized management approaches.


  • Open Access

    Understanding the Variability of Peanut‐Oral Immunotherapy Responses by Multi‐Omics Profiling of Immune Cells

    by Aleix Arnau‐Soler, Sarah E. Ashley, Ahla Ghauri, Alexander C. S. N. Jeanrenaud, Ingo Marenholz, Katharina Blumchen, Penelope Cibin, Alisa Iakupova, Norbert Hubner, Kirsten Beyer, et al.

    Background: Oral immunotherapy (OIT) induces desensitization in peanut allergy, yet 15%–30% of patients do not respond, and a significant risk of anaphylaxis due to treatment remains. In a placebo‐controlled peanut OIT trial, this study identifies molecular drivers of OIT responsiveness through multi‐omics profiling in immune cells. Methods: Immunoglobulins, cytokines, transcriptome, and DNA methylome profiles were analyzed in peanut‐stimulated and unstimulated peripheral blood mononuclear cells isolated from peanut‐allergic children before and after treatment. Multi‐omics profiling focused on OIT responsiveness within the active treatment arm. Additional subgroup analyses were performed to further elucidate molecular mechanisms and potential biomarkers. Results: Complete responders, tolerating 4500 mg of peanut protein, exhibited lower pre‐treatment peanut‐specific IgE and Th2 cytokine production (IL‐4, IL‐5) compared to incomplete responders who tolerated ≤ 1000 mg of peanut protein after treatment. Our primary analysis identified 184 differentially expressed genes and 1001 differentially methylated genes, enriched for innate (ILC3) and adaptive (CD8αα subset of CD8 + T cells) immune cells, alongside γδ T cells and exosomes, highlighting gastrointestinal regulatory processes as central to OIT success. We found a marked downregulation of immunoglobulin genes in patients receiving peanut compared to placebo, suggesting OIT‐induced modulation of B‐cell activity. Functional networks revealed a marked imbalance contrasting regulatory T‐cell responses and B‐cell suppression in the complete responders with innate immune signaling and metabolic stress in the incomplete responders. Conclusion: This multi‐omics approach underscores the importance of gastrointestinal immune mechanisms underlying the variation in peanut oral immunotherapy responses and offers potential biomarkers for improving treatment strategies. Trial Registration: German Clinical Trials Register DRKS00004553


  • Open Access

    Allergen‐Specific IgE is a Stronger Predictor of Remission Following Peanut Oral Immunotherapy Than Age in Children Aged 1–10 Years

    by Sarah E. Ashley, Melanie Lloyd, Paxton Loke, Francesca Orsini, Adriana C. Lozinsky, Michael D. O'SUllivan, Patrick Quinn, Michael Gold, Mimi L. K. Tang

    Background: Remission is the desired outcome following OIT as it allows individuals to discontinue treatment and eat the allergen freely. Early initiation of OIT in infants and toddlers has been embraced as an approach to increase the likelihood of remission. However, there is no high‐quality evidence supporting younger age as an independent factor driving remission; available studies are limited by small samples of younger subjects and lack of adjustment for confounding covariates, particularly peanut‐specific IgE (sIgE) levels which is closely correlated with age. Methods: This study examined relationships between peanut sIgE and age at baseline and remission, in children aged 1–10 who completed 18 months of OIT in the PPOIT‐003 RCT ( n = 162). Remission was defined as absence of clinical reactivity to peanut after 8 weeks of allergen avoidance/treatment discontinuation. Age and sIgE were examined as continuous variables in univariate and multivariate regression models. Results: Higher peanut sIgE was consistently predictive of lower likelihood of remission, independent of age. In contrast, there was no independent association between age and remission after adjusting for baseline sIgE (OR 0.94 [0.79–1.12], p = 0.5). Conclusions: Findings do not support age as an independent predictor of remission following OIT. Additional studies examining safety and efficacy of OIT in infants and younger children are urgently needed, ahead of widespread adoption of early intervention.


  • Open Access

    Allergen specific IgE is a stronger predictor of remission following Peanut Oral Immunotherapy than age in children aged 1-10 years

    by Sarah Ashley, Melanie Lloyd, Paxton Loke, Francesca Orsini, Adriana Chebar Lozinsky Rolnik, Michael O'Sullivan, Patrick Quinn, Michael Gold, Mimi Tang

    Remission is the desired outcome following OIT as it allows individuals to discontinue treatment and eat the allergen freely. Early initiation of OIT in infants and toddlers has been embraced as an approach to increase the likelihood of remission. However, there is no high-quality evidence supporting younger age as an independent factor driving remission; available studies are limited by small samples of younger subjects and lack of adjustment for confounding covariates, particularly peanut-specific IgE (sIgE) levels which is closely correlated with age. This study examined relationships between peanut sIgE and age at baseline and remission, in children aged 1-10 who completed 18 months of OIT in the PPOIT-003 RCT (n=162). Remission was defined as absence of clinical reactivity to peanut after 8 weeks of allergen avoidance/treatment discontinuation. Age and sIgE were examined as continuous variables in univariate and multivariate regression models. Baseline peanut sIgE levels were significantly associated with remission, independent of age (OR 0.1 [0.05-0.22], p<0.001). Higher peanut sIgE was consistently predictive of lower likelihood of remission, independent of age. In contrast, there was no independent association between age and remission after adjusting for baseline sIgE (OR 0.94 [0.79-1.12], p=0.5). Findings do not support age as an independent predictor of remission following OIT. Additional studies examining safety and efficacy of OIT in infants and younger children are urgently needed, ahead of widespread adoption of early intervention.

  • Open Access

    Two‐year post‐treatment outcomes following peanut oral immunotherapy in the Probiotic and Peanut Oral Immunotherapy‐003 Long‐Term ( PPOIT ‐ 003LT ) study

    by Paxton Loke, Xiaofang Wang, Melanie Lloyd, Sarah E. Ashley, Adriana C. Lozinsky, Michael Gold, Michael D. O'SUllivan, Patrick Quinn, Marnie Robinson, Audrey Dunn Galvin, et al.

    Background: Few studies have examined long‐term outcomes following oral immunotherapy (OIT); none have examined long‐term risks and benefits associated with distinct clinical outcomes (desensitization, remission). Methods: Participants completing the probiotic and peanut oral immunotherapy (PPOIT) ‐003 randomized trial were enrolled in a follow‐on study, PPOIT‐003LT. Peanut ingestion, reactions, and health‐related quality of life (HRQOL) were monitored prospectively. Outcomes at 1‐year and 2‐years post‐treatment were examined by treatment group and by post‐OIT clinical outcome (remission, desensitization without remission [DWR], allergic). Results: 86% (151/176) of eligible children enrolled. Post‐treatment peanut ingestion at 2‐years post‐treatment were similar for PPOIT (86.7%) and OIT (78.7%) groups, both higher than placebo (10.3%). Reactions reduced over time for all treatment and clinical outcome groups (PPOIT 31.7% to 23.3%, OIT 37.7% to 19.7%, placebo 13.8% to 6.9%; remission 27.5% to 15.9%; DWR 57.9% to 36.8%; allergic 11.6% to 7%). At 2‐years post‐treatment, similar proportions of remission and allergic participants reported reactions (RD 0.09 (95%CI −0.03, 0.20), p = .127), whereas more DWR participants reported reactions than remission (remission vs DWR: RD −0.21 (95%CI −0.39; −0.03), p = .02) and allergic (DWR vs allergic: RD 0.30 (95%CI 0.13, 0.47), p = .001) participants. At 2‐years post‐treatment, 0% remission versus 5.3% DWR versus 2.3% allergic participants reported adrenaline injector usage. Remission participants had significantly greater HRQOL improvement (adjusted for baseline) compared with both DWR (MD −0.54 (95%CI −0.99, −0.10), p = .017) and allergic (MD −0.82 (95%CI −1.25, −0.38), p < .001). Conclusion: By 2‐years post‐treatment, remission participants reported fewer reactions, less severe reactions and greater HRQOL improvement compared with DWR and allergic participants, indicating that remission is the patient‐preferred treatment outcome over desensitization or remaining allergic.


  • Open Access

    Transcriptomic changes associated with oral immunotherapy for food allergy

    by Sarah E. Ashley, Anthony Bosco, Mimi L. K. Tang

    This review summarizes recent advances in characterizing the transcriptional pathways associated with outcomes following Oral Immunotherapy. Recent technological advances including single‐cell sequencing are transforming the ways in which the transcriptional landscape is understood. The application of these technologies is still in its infancy in food allergy but here we summarize current understanding of gene expression changes following oral immunotherapy for food allergy and specific signatures underpinning the different clinical outcomes of desensitization and remission (sustained unresponsiveness). T helper 2A cells have been identified as a cell type which correlates with disease activity and is modified by treatment. Molecular features at study entry may differentiate individuals who achieve more positive outcomes during OIT. Recent findings point to T cell anergy and Type 1 interferon pathways as potential mechanisms supporting redirection of the allergen‐specific immune response away from allergy towards remission. Despite these developments in our understanding of immune mechanisms following OIT, there are still significant gaps. Additional studies examining immune signatures associated with long term and well‐defined clinical outcomes are required to gain a more complete understanding of the pathways leading to remission of allergy, in order to optimize treatments and gain improved outcomes for patients.